PD35-08 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: POOLED SAFETY ANALYSES FROM RANDOMIZED CONTROLLED STUDIES. (1st May 2022)